Some high-risk patients died during the delay, the research team reported. 

More research on long-term outcomes is still needed before TAVR can be recommended for such patients across the board.

Patients who received TAVR and PCI experienced lower rates of mortality and fewer major bleeding events than those treated with SAVR and CABG. 

The study focused on more than 1,400 TAVR patients treated from August 2007 to June 2018. 

Overall, the team behind the study noted a survival rate of 82.1% after 15 years. 

“The findings of this study will influence shared decision-making between chronic kidney disease patients and the heart team,” one specialist observed. 

The patient-specific models were designed to help clinicians prepare for transcatheter aortic valve replacement (TAVR) procedures.